Xenon Pharmaceuticals Inc. (XENE) — Institutional Holders, Q2 2026 (page 4)

317 institutional investment managers reported a XENE position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $6.1B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 301 to 317. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

XENE 13F holders ranked 301–317 of 317

Institutional investors reporting a position in Xenon Pharmaceuticals Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Allworth Financial#301 · 25 sh$1.5K-34.2%
FIRST HORIZON NATIONAL#302 · 25 sh$1.5K+4.2%
Keating Financial Advisory Services#303 · 20 sh$1.2K+900.0%
MassMutual Private Wealth & , FSB#304 · 17 sh$1.0K0.0%
BESSEMER GROUP#305 · 14 sh$1.0KNew
Park Place Capital#306 · 16 sh$966.000.0%
Physician Wealth Advisors#307 · 13 sh$785.000.0%
Ares Financial Consulting#308 · 12 sh$724.00New
Smartleaf Asset Management#309 · 12 sh$722.000.0%
SHP Wealth Management#310 · 11 sh$664.00New
Cornerstone Financial Management#311 · 10 sh$604.00New
Hughes Financial Services#312 · 5 sh$302.00+25.0%
Caitong International Asset Management , Ltd#313 · 4 sh$241.00-99.9%
Larson Financial Group#314 · 3 sh$181.00-94.2%
TFC Financial Management#315 · 1 sh$61.000.0%
NOMURA ASSET MANAGEMENT LTD#316 · 0 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#317 · 92,740 sh—0.0%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.